Author name: DrugChatter

For the better part of three decades, pharmaceutical companies have monitored what the world says about their drugs through the […]

There’s a certain phase every drug eventually enters once it escapes the controlled environment of clinical trials and lands in

Inside the internet’s endless search for “Can I take this every day forever?” There’s a particular kind of pharmaceutical question

A parent in Texas asks ChatGPT how much ibuprofen to give her 18-month-old. ChatGPT returns a dose calculated for a

The shift happened without a product launch, without a press release, and without a single pharmaceutical company authorizing it. Sometime

There’s a revealing pattern hidden inside patient search behavior. It’s not the ultra-rare oncology agents or impossible-to-pronounce biologics generating the

Walk into any pharmaceutical compliance team’s weekly meeting and you’ll find the same agenda items from the past decade: OPDP

How drug brands fought off-label prescribing to survive: real FDA cases, litigation wins, and what AI monitoring means for pharmacovigilance

There’s a repeating theme across DrugChatter: not “what are the side effects?” but “is this normal—or something I should worry

Pfizer paid $2.3 billion in 2009. GlaxoSmithKline paid $3 billion in 2012. AstraZeneca paid $520 million in 2010. Each of

Every so often the public conversation about medicines drifts into a familiar question: why is this one so expensive? But

There’s a quiet sorting mechanism in medicine that has little to do with pharmacology textbooks and everything to do with